Drug Profile
Tafenoquine - GlaxoSmithKline/60 Degrees Pharmaceuticals
Alternative Names: 60P 003; Arakoda; Etaquine; KODATEF; Kozenis; Krintafel; SB-252263; SB-252263-AAB; SB-252263-AX; Tafenoquine maleate; Tafenoquine succinate; WR 238605; WR 238605 succinateLatest Information Update: 29 Mar 2024
Price :
$50
*
At a glance
- Originator Walter Reed Army Institute of Research
- Developer 60 Degrees Pharmaceuticals; Biocelect; GlaxoSmithKline; GSK; Medicines for Malaria Venture
- Class Aminoquinolines; Antifungals; Antimalarials; Antiprotozoals; Antivirals; Ethers; Fluorinated hydrocarbons; Small molecules
- Mechanism of Action Electron transport complex III inhibitors; Reactive oxygen species stimulants; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - COVID 2019 infections
Highest Development Phases
- Marketed Malaria
- Phase II COVID 2019 infections
- Preclinical Babesiosis; Mycoses
- Discontinued Pneumocystis pneumonia
Most Recent Events
- 29 Mar 2024 Preregistration for Malaria (Combination therapy, In children, Prevention of relapse) in Colombia, Peru (PO) prior to March 2024 (Medicines for Malaria Venture pipeline March 2024)
- 29 Mar 2024 Registered for Malaria (Combination therapy, In adolescents, In adults, Prevention of relapse, In children) in Ethiopia (PO) prior to March 2024 (Medicines for Malaria Venture pipeline March 2024)
- 29 Mar 2024 GSK in collaboration with Medicines for Malaria Venture submits NDA for Malaria (Combination therapy, Prevention of relapse) in multiple endemic countries prior to March 2024 (Medicines for Malaria Venture pipeline March 2024)